Where Cannabis Fits Into Cancer Care
Nausea, vomiting, and loss of appetite are among the most distressing side effects of chemotherapy, and cannabis-derived compounds have a longer, more established history in this area than in almost any other use discussed for medical marijuana. Importantly, the FDA-approved drugs in this space are not raw cannabis — they are synthetic cannabinoid medications that have gone through full clinical trials and regulatory approval.
The FDA-Approved Options: Dronabinol and Nabilone
In 1985, the FDA approved two synthetic forms of THC, dronabinol (brand name Marinol) and nabilone (brand name Cesamet), specifically for chemotherapy-induced nausea and vomiting (CINV) that has not responded adequately to standard antiemetic medications. According to guidance summarized by the American Society of Clinical Oncology (ASCO), these drugs are generally recommended as options for refractory CINV — meaning they are used after first-line antiemetics such as 5-HT3 receptor antagonists, NK1 receptor antagonists, dexamethasone, and olanzapine have already been tried. Clinical data summarized in NCI and NIH-indexed reviews show dronabinol performed better than some older antiemetic drugs (neuroleptics) in head-to-head comparisons, though it is not generally used as a first-line treatment today because newer antiemetics tend to be more effective and have fewer side effects.
- Dronabinol: typically started at 2.5 mg taken up to three times daily, with dosing adjusted by a physician.
- Nabilone: typically started at 1 mg twice daily.
- Both are prescription medications requiring a doctor's supervision, unlike dispensary cannabis products.
What About Smoked or Inhaled Cannabis?
Whole-plant cannabis obtained through a state medical marijuana program is not FDA-approved for CINV, and the clinical trial evidence for inhaled or smoked cannabis in this specific use is considerably thinner than the evidence behind dronabinol and nabilone. The National Cancer Institute's clinician-facing summary on cannabis and cannabinoids notes that many of the available studies on smoked cannabis for CINV are older, smaller, and less rigorously controlled than the trials that supported the synthetic drugs. That does not mean patients report no benefit — many cancer patients describe symptom relief from cannabis products used alongside standard care — but it does mean the evidence bar for smoked or vaporized cannabis products is lower than for the approved pharmaceutical options.
Appetite Stimulation: A More Complicated Story
Cannabis is also widely associated with appetite stimulation, sometimes called "the munchies," and dronabinol carries a separate FDA approval for anorexia associated with weight loss in AIDS patients. However, evidence for cannabis-based appetite stimulation specifically in cancer-related anorexia is mixed. A notable clinical trial published in the Journal of Clinical Oncology compared dronabinol to megestrol acetate, a standard appetite-stimulating drug, in cancer patients with appetite loss, and found megestrol acetate was more effective than dronabinol at improving appetite and weight gain in that trial. This is a useful example of why patient-reported benefits for one symptom (nausea) do not automatically extend to another symptom (appetite) with the same reliability.
What the National Cancer Institute Says
The National Cancer Institute (NCI) maintains a clinician- and patient-facing summary on cannabis and cannabinoids in cancer care, which distinguishes between the FDA-approved synthetic cannabinoid drugs, laboratory and animal research on cannabinoids and tumor biology, and the more limited human clinical evidence for symptom management with cannabis products themselves. The NCI summary is careful to note that laboratory findings suggesting cannabinoids might affect cancer cell growth in animal models have not been established in human clinical trials, and patients should not interpret preclinical research as evidence that cannabis treats cancer itself. Its documented, evidence-supported role remains focused on symptom management — nausea, vomiting, and in some cases pain — rather than as a cancer treatment.
Practical Points for Cancer Patients
- Cannabinoid drugs and cannabis products can interact with other medications, including some chemotherapy agents, so any use should be disclosed to the treating oncology team.
- Smoked cannabis carries respiratory risks that may be especially relevant for patients with compromised lung function or certain cancers.
- Immunocompromised patients undergoing chemotherapy should be aware that raw or unpasteurized cannabis products can carry mold or bacterial contamination risks; oncology teams often advise caution or specific product forms for this reason.
- State medical marijuana programs generally list cancer as a qualifying condition, but rules on product type, potency, and dosing vary by state.
Medical Disclaimer
This article is for general educational purposes only and is not medical advice. It does not diagnose, treat, or cure cancer, chemotherapy side effects, or any other condition, and it is not a substitute for guidance from a licensed oncologist or other qualified healthcare provider. Cancer patients should discuss any use of cannabis, dronabinol, nabilone, or other cannabinoid products with their oncology care team before starting, due to the potential for drug interactions and infection risk during chemotherapy.